Title
Category
Credits
Event date
Cost
  • Adherence
  • Antipsychotics
  • Delivery of Care
  • Psychotic Disorders
  • Schizophrenia/ Schizoaffective Disorders
  • Side Effects
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
What are some of the challenges you face in overcoming adherence issues and providing patient-centered care for people living with schizophrenia? Drs Harvey and Kane offer evidence and clinical experience on these topics in this journal CME activity.
  • Antipsychotics
  • Bipolar Disorder
  • Dementia
  • Diagnostic Tools
  • Schizophrenia/ Schizoaffective Disorders
  • Tardive Dyskinesia
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Can you recognize risk factors for tardive dyskinesia? Are you familiar with diagnostic criteria? Do you regularly assess patients for the condition? Are you knowledgeable about using new medications for TD? Experts share best practices for the assessment and treatment of TD.
  • Diagnostic Tools
  • Sleep
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Drs Rosenberg and Krystal identify key steps in the diagnosis and treatment of insomnia disorder.
  • Antipsychotics
  • Diagnostic Tools
  • Movement Disorders
  • Patient/Physician Communication
  • Schizophrenia/ Schizoaffective Disorders
  • Tardive Dyskinesia
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Although clinicians are pressed for time, diligence in assessing for tardive dyskinesia in patients taking antipsychotics is crucial, especially now that treatment is available. In this brief CME activity, Dr Nierenberg describes the evaluation process. 
  • Antipsychotics
  • Movement Disorders
  • Neurology
  • Patient/Physician Communication
  • Tardive Dyskinesia
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Do you know how to talk with your patients about the risk for tardive dyskinesia? Follow along as Dr Nierenberg offers tips for clear communication.
  • Myasthenia Gravis
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Patients with generalized myasthenia gravis (gMG) receive multiple immunosuppressive therapies, but with incomplete suppression of IgG autoantibodies. Read this rapid update in gMG to learn about novel therapies that can more effectively suppress IgG autoantibodies through a novel mechanism of action to help your patients achieve better clinical outcomes.
  • Anticonvulsants
  • Epilepsy
  • Neurology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Drs Detyniecki and Penovich identify the need for emergency seizure response plans and the new rescue treatment options that may easily be used by patients with epilepsy and their caregivers.
  • Antipsychotics
  • Bipolar Disorder
  • Depression
  • Movement Disorders
  • Schizophrenia/ Schizoaffective Disorders
  • Tardive Dyskinesia
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
In brief videos, Drs McEvoy and Nierenberg discuss symptoms of tardive dyskinesia (TD), how to observe patients (whether in person or via telemedicine), and how to educate patients and families about TD.
  • Diagnostic Tools
  • Patient/Physician Communication
  • Sleep
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
To diagnose insomnia disorder, how do you conduct an effective interview with patients? What assessment tools do you use? Review the evaluation process with an expert.
  • Anticonvulsants
  • Epilepsy
  • Neurology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Seizure clusters take a toll on patients’ emotional wellbeing, work, and quality of life. Learn from experts about new rescue treatments.

Pages